Bill Text: TX HB1011 | 2011-2012 | 82nd Legislature | Introduced
Bill Title: Relating to the addition of certain synthetic derivatives of marihuana and Saliva divinorum and its derivatives and extracts to the Texas Controlled Substances Act.
Sponsorship: Partisan Bill (Republican 1)
Status: (Introduced - Dead) 2011-03-15 - Left pending in committee [HB1011 Detail]
Download: Texas-2011-HB1011-Introduced.html
| 82R1624 JSC-D | ||
| By: Bonnen | H.B. No. 1011 | |
|
|
||
|
|
||
| relating to the addition of certain synthetic derivatives of | ||
| marihuana and Saliva divinorum and its derivatives and extracts to | ||
| the Texas Controlled Substances Act. | ||
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
| SECTION 1. Section 481.103(a), Health and Safety Code, is | ||
| amended to read as follows: | ||
| (a) Penalty Group 2 consists of: | ||
| (1) any quantity of the following hallucinogenic | ||
| substances, their salts, isomers, and salts of isomers, unless | ||
| specifically excepted, if the existence of these salts, isomers, | ||
| and salts of isomers is possible within the specific chemical | ||
| designation: | ||
| alpha-ethyltryptamine; | ||
| alpha-methyltryptamine; | ||
| 4-bromo-2, 5-dimethoxyamphetamine (some trade or | ||
| other names: 4-bromo-2, 5-dimethoxy-alpha-methylphenethylamine; | ||
| 4-bromo-2, 5-DMA); | ||
| 4-bromo-2, 5-dimethoxyphenethylamine; | ||
| Bufotenine (some trade and other names: 3-(beta- | ||
| Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)- 5- | ||
| indolol; N, N-dimethylserotonin; 5-hydroxy-N, N- | ||
| dimethyltryptamine; mappine); | ||
| Diethyltryptamine (some trade and other names: N, | ||
| N-Diethyltryptamine, DET); | ||
| 2, 5-dimethoxyamphetamine (some trade or other | ||
| names: 2, 5-dimethoxy-alpha-methylphenethylamine; 2, 5-DMA); | ||
| 2, 5-dimethoxy-4-ethylamphetamine (trade or other | ||
| name: DOET); | ||
| 2, 5-dimethoxy-4-(n)-propylthiophenethylamine | ||
| (trade or other name: 2C-T-7); | ||
| Dimethyltryptamine ( trade or other name: DMT); | ||
| Dronabinol (synthetic) in sesame oil and | ||
| encapsulated in a soft gelatin capsule in a U.S. Food and Drug | ||
| Administration approved drug product (some trade or other names for | ||
| Dronabinol: (a6aR-trans)-6a,7,8,10a-tetrahydro- 6,6, 9- | ||
| trimethyl-3-pentyl-6H- dibenzo [b,d]pyran-1-ol or (-)-delta-9- | ||
| (trans)- tetrahydrocannabinol); | ||
| Ethylamine Analog of Phencyclidine (some trade or | ||
| other names: N-ethyl-1-phenylcyclohexylamine, (1- | ||
| phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, | ||
| cyclohexamine, PCE); | ||
| Ibogaine (some trade or other names: 7-Ethyl-6, 6, | ||
| beta 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H- | ||
| pyrido [1', 2':1, 2] azepino [5, 4-b] indole; tabernanthe iboga.); | ||
| Mescaline; | ||
| 5-methoxy-N, N-diisopropyltryptamine; | ||
| 5-methoxy-3, 4-methylenedioxy amphetamine; | ||
| 4-methoxyamphetamine (some trade or other names: | ||
| 4-methoxy-alpha-methylphenethylamine; paramethoxyamphetamine; | ||
| PMA); | ||
| 1-methyl- 4-phenyl-4-propionoxypiperidine (MPPP, | ||
| PPMP); | ||
| 4-methyl-2, 5-dimethoxyamphetamine (some trade | ||
| and other names: 4-methyl-2, 5-dimethoxy-alpha- | ||
| methylphenethylamine; "DOM"; "STP"); | ||
| 3,4-methylenedioxy methamphetamine (MDMA, MDM); | ||
| 3,4-methylenedioxy amphetamine; | ||
| 3,4-methylenedioxy N-ethylamphetamine (Also | ||
| known as N-ethyl MDA); | ||
| Nabilone (Another name for nabilone: (+)-trans- | ||
| 3-(1,1-dimethylheptyl)- 6,6a, 7,8,10,10a-hexahydro-1-hydroxy- 6, | ||
| 6-dimethyl-9H-dibenzo[b,d] pyran-9-one; | ||
| N-benzylpiperazine (some trade or other names: | ||
| BZP; 1-benzylpiperazine); | ||
| N-ethyl-3-piperidyl benzilate; | ||
| N-hydroxy-3,4-methylenedioxyamphetamine (Also | ||
| known as N-hydroxy MDA); | ||
| 4-methylaminorex; | ||
| N-methyl-3-piperidyl benzilate; | ||
| Parahexyl (some trade or other names: 3-Hexyl-1- | ||
| hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo [b, d] | ||
| pyran; Synhexyl); | ||
| 1-Phenylcyclohexylamine; | ||
| 1-Piperidinocyclohexanecarbonitrile (PCC); | ||
| Psilocin; | ||
| Psilocybin; | ||
| Pyrrolidine Analog of Phencyclidine (some trade | ||
| or other names: 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP); | ||
| Tetrahydrocannabinols, other than marihuana, and | ||
| synthetic equivalents of the substances contained in the plant, or | ||
| in the resinous extractives of Cannabis, or synthetic substances, | ||
| derivatives, and their isomers with similar chemical structure and | ||
| pharmacological activity such as: | ||
| (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl- | ||
| 3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c] chromen-1- | ||
| ol) (Also known as HU-210); | ||
| 1-butyl-3-(1-naphthoyl)indole (Also known | ||
| as JWH-073); | ||
| delta-1 cis or trans tetrahydrocannabinol, | ||
| and their optical isomers; | ||
| delta-6 cis or trans tetrahydrocannabinol, | ||
| and their optical isomers; | ||
| delta-3, 4 cis or trans | ||
| tetrahydrocannabinol, and its optical isomers; | ||
| 1-pentyl-3-(1-naphthoyl)indole (Also known | ||
| as JWH-018); | ||
| compounds of these structures, regardless of | ||
| numerical designation of atomic positions, since nomenclature of | ||
| these substances is not internationally standardized; | ||
| Thiophene Analog of Phencyclidine (some trade or | ||
| other names: 1-[1-(2-thienyl) cyclohexyl] piperidine; 2-Thienyl | ||
| Analog of Phencyclidine; TPCP, TCP); | ||
| 1-pyrrolidine (some trade or other name: TCPy); | ||
| 1-(3-trifluoromethylphenyl)piperazine (trade or | ||
| other name: TFMPP); and | ||
| 3,4,5-trimethoxy amphetamine; | ||
| (2) Phenylacetone (some trade or other names: | ||
| Phenyl-2-propanone; P2P, Benzymethyl ketone, methyl benzyl | ||
| ketone); and | ||
| (3) unless specifically excepted or unless listed in | ||
| another Penalty Group, a material, compound, mixture, or | ||
| preparation that contains any quantity of the following substances | ||
| having a potential for abuse associated with a depressant or | ||
| stimulant effect on the central nervous system: | ||
| Aminorex (some trade or other names: aminoxaphen; | ||
| 2-amino-5-phenyl-2-oxazoline; 4,5-dihydro-5-phenyl-2- | ||
| oxazolamine); | ||
| Amphetamine, its salts, optical isomers, and | ||
| salts of optical isomers; | ||
| Cathinone (some trade or other names: 2-amino-1- | ||
| phenyl-1-propanone, alpha-aminopropiophenone, 2- | ||
| aminopropiophenone); | ||
| Etorphine Hydrochloride; | ||
| Fenethylline and its salts; | ||
| Lisdexamfetamine, including its salts, isomers, | ||
| and salts of isomers; | ||
| Mecloqualone and its salts; | ||
| Methaqualone and its salts; | ||
| Methcathinone (some trade or other names: 2- | ||
| methylamino-propiophenone; alpha-(methylamino)propriophenone; | ||
| 2-(methylamino)-1-phenylpropan-1-one; alpha-N- | ||
| methylaminopropriophenone; monomethylpropion; ephedrone, N- | ||
| methylcathinone; methylcathinone; AL-464; AL-422; AL-463; and UR | ||
| 1431); | ||
| N-Ethylamphetamine, its salts, optical isomers, | ||
| and salts of optical isomers; and | ||
| N,N-dimethylamphetamine (some trade or other | ||
| names: N,N,alpha-trimethylbenzeneethaneamine; | ||
| N,N,alpha-trimethylphenethylamine), its salts, optical isomers, | ||
| and salts of optical isomers. | ||
| SECTION 2. Section 481.104(a), Health and Safety Code, is | ||
| amended to read as follows: | ||
| (a) Penalty Group 3 consists of: | ||
| (1) a material, compound, mixture, or preparation that | ||
| contains any quantity of the following substances having a | ||
| potential for abuse associated with a stimulant effect on the | ||
| central nervous system: | ||
| Methylphenidate and its salts; and | ||
| Phenmetrazine and its salts; | ||
| (2) a material, compound, mixture, or preparation that | ||
| contains any quantity of the following substances having a | ||
| potential for abuse associated with a depressant effect on the | ||
| central nervous system: | ||
| a substance that contains any quantity of a | ||
| derivative of barbituric acid, or any salt of a derivative of | ||
| barbituric acid not otherwise described by this subsection; | ||
| a compound, mixture, or preparation containing | ||
| amobarbital, secobarbital, pentobarbital, or any salt of any of | ||
| these, and one or more active medicinal ingredients that are not | ||
| listed in any penalty group; | ||
| a suppository dosage form containing amobarbital, | ||
| secobarbital, pentobarbital, or any salt of any of these drugs, and | ||
| approved by the United States Food and Drug Administration for | ||
| marketing only as a suppository; | ||
| Alprazolam; | ||
| Amobarbital; | ||
| Bromazepam; | ||
| Camazepam; | ||
| Chlordiazepoxide; | ||
| Chlorhexadol; | ||
| Clobazam; | ||
| Clonazepam; | ||
| Clorazepate; | ||
| Clotiazepam; | ||
| Cloxazolam; | ||
| Delorazepam; | ||
| Diazepam; | ||
| Estazolam; | ||
| Ethyl loflazepate; | ||
| Fludiazepam; | ||
| Flurazepam; | ||
| Glutethimide; | ||
| Halazepam; | ||
| Haloxzolam; | ||
| Ketazolam; | ||
| Loprazolam; | ||
| Lorazepam; | ||
| Lormetazepam; | ||
| Lysergic acid, including its salts, isomers, and | ||
| salts of isomers; | ||
| Lysergic acid amide, including its salts, | ||
| isomers, and salts of isomers; | ||
| Mebutamate; | ||
| Medazepam; | ||
| Methyprylon; | ||
| Midazolam; | ||
| Nimetazepam; | ||
| Nitrazepam; | ||
| Nordiazepam; | ||
| Oxazepam; | ||
| Oxazolam; | ||
| Pentazocine, its salts, derivatives, or compounds | ||
| or mixtures thereof; | ||
| Pentobarbital; | ||
| Pinazepam; | ||
| Prazepam; | ||
| Quazepam; | ||
| Secobarbital; | ||
| Sulfondiethylmethane; | ||
| Sulfonethylmethane; | ||
| Sulfonmethane; | ||
| Temazepam; | ||
| Tetrazepam; | ||
| Tiletamine and zolazepam in combination, and its | ||
| salts. (some trade or other names for a tiletamine-zolazepam | ||
| combination product: Telazol, for tiletamine: 2-(ethylamino)- | ||
| 2-(2-thienyl)-cyclohexanone, and for zolazepam: 4-(2- | ||
| fluorophenyl)-6, 8-dihydro-1,3,8,-trimethylpyrazolo-[3,4- | ||
| e](1,4)-d diazepin-7(1H)-one, flupyrazapon); | ||
| Triazolam; | ||
| Zaleplon; | ||
| Zolpidem; and | ||
| Zopiclone; | ||
| (3) Nalorphine; | ||
| (4) a material, compound, mixture, or preparation | ||
| containing limited quantities of the following narcotic drugs, or | ||
| any of their salts: | ||
| not more than 1.8 grams of codeine, or any of its | ||
| salts, per 100 milliliters or not more than 90 milligrams per dosage | ||
| unit, with an equal or greater quantity of an isoquinoline alkaloid | ||
| of opium; | ||
| not more than 1.8 grams of codeine, or any of its | ||
| salts, per 100 milliliters or not more than 90 milligrams per dosage | ||
| unit, with one or more active, nonnarcotic ingredients in | ||
| recognized therapeutic amounts; | ||
| not more than 300 milligrams of dihydrocodeinone | ||
| (hydrocodone), or any of its salts, per 100 milliliters or not more | ||
| than 15 milligrams per dosage unit, with a fourfold or greater | ||
| quantity of an isoquinoline alkaloid of opium; | ||
| not more than 300 milligrams of dihydrocodeinone | ||
| (hydrocodone), or any of its salts, per 100 milliliters or not more | ||
| than 15 milligrams per dosage unit, with one or more active, | ||
| nonnarcotic ingredients in recognized therapeutic amounts; | ||
| not more than 1.8 grams of dihydrocodeine, or any | ||
| of its salts, per 100 milliliters or not more than 90 milligrams per | ||
| dosage unit, with one or more active, nonnarcotic ingredients in | ||
| recognized therapeutic amounts; | ||
| not more than 300 milligrams of ethylmorphine, or | ||
| any of its salts, per 100 milliliters or not more than 15 milligrams | ||
| per dosage unit, with one or more active, nonnarcotic ingredients | ||
| in recognized therapeutic amounts; | ||
| not more than 500 milligrams of opium per 100 | ||
| milliliters or per 100 grams, or not more than 25 milligrams per | ||
| dosage unit, with one or more active, nonnarcotic ingredients in | ||
| recognized therapeutic amounts; | ||
| not more than 50 milligrams of morphine, or any of | ||
| its salts, per 100 milliliters or per 100 grams with one or more | ||
| active, nonnarcotic ingredients in recognized therapeutic amounts; | ||
| and | ||
| not more than 1 milligram of difenoxin and not | ||
| less than 25 micrograms of atropine sulfate per dosage unit; | ||
| (5) a material, compound, mixture, or preparation that | ||
| contains any quantity of the following substances: | ||
| Barbital; | ||
| Chloral betaine; | ||
| Chloral hydrate; | ||
| Ethchlorvynol; | ||
| Ethinamate; | ||
| Meprobamate; | ||
| Methohexital; | ||
| Methylphenobarbital (Mephobarbital); | ||
| Paraldehyde; | ||
| Petrichloral; and | ||
| Phenobarbital; | ||
| (6) Peyote, unless unharvested and growing in its | ||
| natural state, meaning all parts of the plant classified | ||
| botanically as Lophophora, whether growing or not, the seeds of the | ||
| plant, an extract from a part of the plant, and every compound, | ||
| manufacture, salt, derivative, mixture, or preparation of the | ||
| plant, its seeds, or extracts; | ||
| (7) unless listed in another penalty group, a | ||
| material, compound, mixture, or preparation that contains any | ||
| quantity of the following substances having a stimulant effect on | ||
| the central nervous system, including the substance's salts, | ||
| optical, position, or geometric isomers, and salts of the | ||
| substance's isomers, if the existence of the salts, isomers, and | ||
| salts of isomers is possible within the specific chemical | ||
| designation: | ||
| Benzphetamine; | ||
| Cathine [(+)-norpseudoephedrine]; | ||
| Chlorphentermine; | ||
| Clortermine; | ||
| Diethylpropion; | ||
| Fencamfamin; | ||
| Fenfluramine; | ||
| Fenproporex; | ||
| Mazindol; | ||
| Mefenorex; | ||
| Modafinil; | ||
| Pemoline (including organometallic complexes and | ||
| their chelates); | ||
| Phendimetrazine; | ||
| Phentermine; | ||
| Pipradrol; | ||
| Sibutramine; and | ||
| SPA [(-)-1-dimethylamino-1,2-diphenylethane]; | ||
| (8) unless specifically excepted or unless listed in | ||
| another penalty group, a material, compound, mixture, or | ||
| preparation that contains any quantity of the following substance, | ||
| including its salts: | ||
| Dextropropoxyphene (Alpha-(+)-4-dimethylamino- | ||
| 1,2-diphenyl-3-methyl-2-propionoxybutane); [ |
||
| (9) an anabolic steroid, including any drug or | ||
| hormonal substance, or any substance that is chemically or | ||
| pharmacologically related to testosterone, other than an estrogen, | ||
| progestin, dehydroepiandrosterone, or corticosteroid, and promotes | ||
| muscle growth, including the following drugs and substances and any | ||
| salt, ester, or ether of the following drugs and substances: | ||
| Androstanediol; | ||
| Androstanedione; | ||
| Androstenediol; | ||
| Androstenedione; | ||
| Bolasterone; | ||
| Boldenone; | ||
| Calusterone; | ||
| Clostebol; | ||
| Dehydrochlormethyltestosterone; | ||
| Delta-1-dihydrotestosterone; | ||
| Dihydrotestosterone (4-dihydrotestosterone); | ||
| Drostanolone; | ||
| Ethylestrenol; | ||
| Fluoxymesterone; | ||
| Formebulone; | ||
| Furazabol; | ||
| 13beta-ethyl-17beta-hydroxygon-4-en-3-one; | ||
| 4-hydroxytestosterone; | ||
| 4-hydroxy-19-nortestosterone; | ||
| Mestanolone; | ||
| Mesterolone; | ||
| Methandienone; | ||
| Methandriol; | ||
| Methenolone; | ||
| 17alpha-methyl-3beta, 17 beta-dihydroxy-5alpha- | ||
| androstane; | ||
| 17alpha-methyl-3alpha, 17 beta-dihydroxy-5alpha- | ||
| androstane; | ||
| 17alpha-methyl-3beta, 17beta-dihydroxyandrost-4- | ||
| ene; | ||
| 17alpha-methyl-4-hydroxynandrolone; | ||
| Methyldienolone; | ||
| Methyltestosterone; | ||
| Methyltrienolone; | ||
| 17alpha-methyl-delta-1-dihydrotestosterone; | ||
| Mibolerone; | ||
| Nandrolone; | ||
| Norandrostenediol; | ||
| Norandrostenedione; | ||
| Norbolethone; | ||
| Norclostebol; | ||
| Norethandrolone; | ||
| Normethandrolone; | ||
| Oxandrolone; | ||
| Oxymesterone; | ||
| Oxymetholone; | ||
| Stanozolol; | ||
| Stenbolone; | ||
| Testolactone; | ||
| Testosterone; | ||
| Tetrahydrogestrinone; and | ||
| Trenbolone; and | ||
| (10) Salvia divinorum, unless unharvested and growing | ||
| in its natural state, meaning all parts of that plant, whether | ||
| growing or not, the seeds of that plant, an extract from a part of | ||
| that plant, and every compound, manufacture, salt, derivative, | ||
| mixture, or preparation of that plant, its seeds, or extracts, | ||
| including Salvinorin A. | ||
| SECTION 3. This Act takes effect September 1, 2011. | ||
